13393 results about "Ultrafiltration" patented technology

Disclosed and claimed are a method for the purification of polysaccharide-protein conjugate vaccines by ultrafiltration in a saturated solution of ammonium sulfate. The ultrafiltration method of the present invention provides an efficient, readily scalable method for removal of unbound polysaccharides from polysaccharide-protein vaccines, thereby improving the purity and consistency of the polysaccharide-protein vaccines.

A process for producing a kakadu plum powder having an increased amount of naturally occurring ascorbic acid and high ORAC value. The process of preparing the extract includes the following: disintegrating kakadu plum fruit; treating the disintegrated kakadu plum material with enzymes to at least partially digest the material; juicing the kakadu plum material and drying the juice to produce a powder. In a preferred embodiment, the kakadu plum juice is further clarified with ultrafiltration and concentrated by performing reverse osmosis on the kakadu plum juice. The resultant kakadu plum powder has a natural ascorbic acid content of at least about 15% and a naturally occurring Oxygen Reduction Absorption Capacity value of at least 1500.

The volume of fluid removed from a patient during ultrafiltration is controlled automatically on the basis of central venous pressure (CVP) measurements. In one embodiment, a central venous catheter (CVC) is used for accessing blood during dialysis. A sensor located at the tip of the catheter or inside the dialysis machine is used to periodically measure CVP. CVP feedback data helps prevent the excessive removal of fluids from the patient.

A system, program product and method continuously optimize an ultrafiltration rate during an extracorporeal renal replacement process by modeling physiological and actual rate data. The system maps the sensed, physiological data to a mathematical model to assess the data in terms of the ultrafiltration rate. The model provides parameters used to predict where the treatment is headed based on current conditions. The system processes the parameters in terms of preset criteria to generate the optimized ultrafiltration rate. Where the system is networked, communication of the data may be accomplished using remote and online communication techniques.

Systems and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The dialysis circuit and an extracorporeal circuit for circulating blood are in fluid communication through the dialysis membrane. The flux of fluid moving between the extracorporeal circuit and the dialysis circuit is modified by the rate at which the control pump is operating such that a rate of ultrafiltration and convective clearance can be controlled. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to provide a facility to quantify or monitor the removal of urea by the sorbent cartridge.

The present invention is directed to novel systems for conducting the filtration of blood using manifolds. The manifolds integrate various sensors and have fluid pathways formed therein to direct fluids from various sources through the requisite blood filtration or ultrafiltration system steps.

A number of improvements relating to methods and apparatuses for kidney dialysis are disclosed. These include checking of dialysate bypass status using flow measurement; using a flow sensor to confirm the absence of ultrafiltration during bypass; automatic testing of ultrafiltration function by removal of a discrete volume from a portion of the dialysate flow path coupled with a pressure test of that part of the flow path; using a touch screen user interface; bar graph profile programming of ultrafiltration, sodium, and bicarbonate parameters; using a RAM card to upload treatment instructions to, and to download treatment data from, the machine; automatic setting of proportioning mode (acetate or bicarbonate) based on connections of concentrate lines; predicting dialysate conductivity values based on brand and formulation of concentrates; minimizing no-flow dead time between dialysate pulses; initiating operation in a timed mode from a machine power-off condition; preserving machine mode during machine power-fail condition; calibration scheduling and reminding; automatic level adjusting; and blood leak flow rate detecting.

A cardiorenal patient monitoring system comprising, either implanted or non-implanted device(s), remote peripheral device(s), computer network(s), host, and communication means between the device(s), computer network(s), and host. The preferred embodiment shows an advanced patient monitoring system for using an implanted cardiac device and a dialysis machine in renal therapy. In addition, the method of advanced patient monitoring is in conjunction with the advanced patient monitoring system is disclosed.

An integrated disposable cartridge for dialysis or ultrafiltration treatment of blood is disclosed that includes integral miniature pressure sensors. Sensors are embedded in the tubing of the cartridge to measure pressure of blood or other fluids. Cartridge elements form a continuous smooth bore passage for blood that reduces probability of clotting.

A method and plant for the treatment of an organic waste material in liquid form, e.g. liquid manure from livestock, the method comprising filtering fibres and particles from the liquid, subjecting the liquid to anaerobic fermentation in a biogas reactor, separating a substantially sterile and particle-free permeate stream from the biogas reactor, e.g. using ultrafiltration, subjecting the permeate stream to treatment with an ammonia stripper at an elevated temperature and preferably at reduced pressure to remove substantially all ammonia and carbon dioxide and to result in an ammonia fraction and a nutrient salt fraction, and separating the nutrient salt fraction into a fertiliser concentrate fraction and a water fraction, e.g. using reverse osmosis. The end products of the method are clean water, ammonia concentrate, fertiliser concentrate containing salts of P and K, compost and high-quality biogas with a high methane content.

A hemodialysis apparatus includes a dialyzing device, a measuring device and a calculation device. The dialyzing device dialyzes and ultrafiltrates blood of a patient circulating extracorporeally to perform hemodialysis treatment. The measuring device measures a variation rate of a body weight of the patient and a variation rate of a predetermined blood benchmark during the hemodialysis treatment using the dialyzing device. The calculation device calculates, during the hemodialysis treatment, a parameter relating the variation rate of the body weight and the variation rate of the predetermined blood benchmark to each other, and correlating to a dry weight of the patient.

Systems and methods are disclosed for performing hemodialysis that include fluid handling systems that provide accurate control over the type and level of hemodialysis being performed. The system includes a first pump for pumping dialysate into a dialyzer and a second pump for pumping dialysate out of the dialyzer. The system also includes a third pump that provides improved control of a level of ultrafiltration, hemodiafiltration, or both.

A batch of dialysate solution is made from a mixture of bicarbonate formulation and a liquid acid formulation. The liquid acid formulation is introduced into a dialysate tank and then removed from the tank and stored elsewhere, such as in an ultrafiltration tank, where it is diluted with a few litres of water. The dialysate tank is then filled with water and the bicarbonate formulation is added to the dialysate tank. The bicarbonate formulation is mixed and dissolved by circulation in a closed loop, with the liquid acid formulation kept separate. When the bicarbonate solution has been prepared, the liquid acid solution and the bicarbonate solution are mixed together and stored in the dialysate preparation tank. An additional quantity of dilution water is introduced into the dialysate system to bring the final conductivity down to the desired range. The excess dialysate solution can be used for several purposes, such as an endotoxin flush of the blood tubing set or a dialyzer clearance test.

A method and apparatus for ultrafiltration of blood operating by removing blood from a peripheral blood vessel at a rate of less than two percent of total cardiac output of a patient, extracting fluid at a rate of 0.1 liter to 1.0 liters per hour while retaining cells and proteins in the blood, and returning the concentrated blood to a secondary blood vessel is disclosed. Blood is removed and returned using small gage needles. As a pump circulates blood from the patient, a filter removes ultrafiltrate from the blood using duty cycle or pump control, and a transparent container collects the removed fluid.

The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and / or one of its variants and / or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore relates to highly concentrated, liquid formulations of anti-EGFR antibodies, in particular of monoclonal antibodies against the EGF receptor, particularly preferably Mab C225 (cetuximab) and Mab h425 (EMD 72000) and / or variants and / or fragments thereof, characterised in that the highly concentrated, liquid formulations have a content of anti-EGFR antibodies of 10-250, preferably 50-180 mg / ml, particularly preferably of 100-150 mg / ml, and to the use thereof.

The present invention relates to ultrafiltration. In particular, the present invention provides nanoporous membranes having pores for generating in vitro and in vivo ultrafiltrate, devices and bioartificial organs utilizing such nanoporous membranes, and related methods (e.g., diagnostic methods, research methods, drug screening). The present invention further provides nanoporous membranes configured to avoid protein fouling with, for example, a polyethylene glycol surface coating.

The invention relates to the fields of environmental technology and the breeding and processing of microalgae, in particular to a method for producing feed additive from livestock and poultry breeding wastewater and purifying breeding wastewater to reclaimed water. The method is characterized by comprising the following steps that: wastewater enters an acidification adjusting tank through a grille, and the acidified wastewater enters an anaerobic biochemical reactor for treatment and then enters an aerobic biochemical reactor; after the aerobic biochemical treatment, the obtained biogas slurry enters a settling tank for settling, the supernatant enters a membrane bioreactor for further aerobic treatment and is filtered by an ultrafiltration membrane, the generated ultrafiltration clear liquid is sterilized and neutralized and then enters a photobioreactor, algae are added into the photobioreactor to perform microalgae cultivation, and the algae liquid is discharged from the photobioreactor and then enters a flocculation and settling tank; and after flocculation and settling, the supernatant is used for water recycling, the concentrated algae liquid at the bottom enters a filter, and the separated microalgae slurry enters a fermentation / enzymolysis pot (tank) to perform fermentation / enzymolysis to be used as the feed additive. The invention has the advantages of high economic adaptability, zero discharge and the like.

A tube assembly, system and method for biological waste containment for sample collection, and for ultrafiltration collection. In one embodiment, the tube assembly of the present invention includes a first tube, a second tube, a mechanism for securing the first and second tubes, and at least one container for operable connection to one or both of the first and second tubes. The securing mechanism orients the first ends of the first and second tubes in a manner such that the first end of the first tube extends beyond the first end of the second tube an interstitial space is created between the outer diameter of the first tube and the inner diameter of the second tube. The tubing mechanism is utilized for retrieval of a biological fluid through the first tube, flushing the first tube and the second tube with a rinse solution, and extraction of waste through the second tube into a waste container. The tubing mechanism is also utilized for retrieval of collection samples with the addition of a vacuum source and sealed manifold.

The present invention relates to dialysis solutions for peritoneal dialysis, containing hydroxyethyl starch as the osmotically-active substance, electrolytes and, optionally, conventional additives, where the hydroxyethyl starch has a molecular weight Mw in the range from 10,000 to 150,000, a substitution MS in the range from 0.10 to 0.40, a substitution DS in the range from 0.09 to 0.35 and a substitution ratio C2 / C6>=8. With this peritoneal dialysis solution it is possible, with an outstanding ultrafiltration, to maintain a longer dwell time, for example the dialysis solution can be utilized for a period of 12 hours in the CAPD without replacement. In addition, the inventive dialysis solution is also particularly advantageous for patients with residual kidney function. The resorption of the osmotically active substance is clearly diminished and even after a dwell time of 12 hours it amounts to a maximum of 60-70%.

A hemodialysis treatment apparatus includes a circulating blood volume variation rate detecting device, a vital sign detecting device and a display. The circulating blood volume variation rate detecting device detects a circulating blood volume variation rate of a patient in a time-course of a hemodialysis treatment. The vital sign detecting device detects a vital sign value of the patient in the time-course of the hemodialysis treatment. The display has a screen and displays both the circulating blood volume variation rate and the vital sign value on the screen along a time scale. The hemodialysis treatment apparatus dialyzes and ultrafiltrates extracorporeally circulating blood of the patient to perform the hemodialysis treatment.

A process is described for treating an approximately neutral fluid milk composition, including milk protein concentrate and milk plus added whey, by selecting an alkali, adjusting the pH upward, heating, cooling, selecting an acid, and adjusting the pH down before ultrafiltering and, in a more preferred process, thereafter diafiltering the treated composition. Selection of the appropriate alkali, pH values, temperatures, acid, and membrane filter porosity results in improved yields of retentate proteins having selected compositions with improved utility, including a more palatable flavor, a brod range of solution viscosities, an increase in the solubility of the dried retentates in cold water to nearly 100%, and an increase in the calcium content of the membrane filtered retentate by about 50% compared to a similar retentate from standard milk. Appropriate selection of processing conditions can result in at least one filter permeate with a protein composition enriched in alpha lactalbumin, a protein that is highly beneficial for human nutrition.

The invention discloses a treatment method of high saline wastewater, and relates to the treatment technology. The method comprises the following steps: preparing high saline wastewater, regulating in a regulating pond, chemically pre-treating in a settling pond, filtering in a V-shaped filter pond, the first section ion exchange softening, ultrafiltering in an ultrafiltration system, reverse osmosis treating through a first section reverse osmosis system, the second ion exchange softening, nano-filtering through a high-pressure nano-filtration system, nano-filtering to produce water, reverse osmosis treating through a second section reverse osmosis system, concentrating through a first section high-pressure flat film system, MVR evaporating and crystallizing to obtain the industrial level sodium chloride; nano-filtering to concentrate water, concentrating through a second section high pressure flat film system, freezing and crystallizing to obtain the industrial level mirabilite. The ultra-filtration, the nano-filtration, the reverse osmosis and high-pressure flat film methods are reasonably coupled to combine with the MVR crystallization and freezing crystallization to treat the high saline wastewater, the defect of single technology is overcome, the combination advantage is developed, the problems of efficiently and economically treating and recycling the high saline wastewater can be solved, and the treatment method has obvious economic benefit and social benefit.

A method and system for the extracorporeal treatment of blood to remove fluid from the fluid overloaded patient is disclosed that non-invasively measures an oxygen level in the venous blood. The oxygen blood level is used to detect when hypotension is about to occur in a patient. The oxygen level measurements are used as feedback signals. These feedback signals are applied to automatically control the rate of fluid extraction to achieve the desired clinical outcome and avoid precipitating a hypotensive crisis in the patient.